DTC Ad Comparative Claims Draw FDA Criticism, Even With “Scientific Basis”
This article was originally published in The Pink Sheet Daily
Executive Summary
“We’re not pleased with the way direct-to-consumer advertising is going,” Acting Commissioner Crawford says. DTC ads have become “ridiculous,” he says; “very strong measures” by FDA may be warranted.
You may also be interested in...
Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says
The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.
Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says
The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.
FDA Planning Enforcement Response To DTC Ads Aired Last Weekend
Acting Commissioner Crawford has formed an "informal" task force to "see if there is a violation we can pursue." Erectile dysfunction ads are a particular sore point, Crawford indicates. Action could come before the end of the week.